RxDoctor Payments Data

Richard Crane, MD

Internal Medicine · Supply, NCNPI 1013096486

Payments from drug & device makers

$2,226in general payments, 2019–2025

Across 146 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$263
  • Pfizer$260
  • Lilly USA, LLC$234
  • Amarin Pharma, Inc.$225
  • Astellas Pharma US Inc$203
  • Boehringer Ingelheim$179
  • plus $862 from 19 others

What the payments were for

  • Food & beverage$2,12095%
  • Education$1065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,226 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$397,600
Medicare patients
380
Services billed
13,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$99,928
OzempicSemaglutide57$67,150
XareltoRivaroxaban56$57,990
JardianceEmpagliflozin38$36,245
Repatha SureclickEvolocumab40$36,143
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$20,481
MounjaroTirzepatide20$18,712
Spiriva RespimatTiotropium Bromide19$17,521
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,523
RybelsusSemaglutide13$11,839
Combivent RespimatIpratropium/Albuterol Sulfate12$8,796
NexlizetBempedoic Acid/Ezetimibe13$7,836
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$7,384
OxycontinOxycodone Hcl18$7,006
Tresiba Flextouch U-100Insulin Degludec14$6,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$260$106,346152 claims
Novo NordiskOzempic, Rybelsus$116$78,99070 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$179$69,94682 claims
Johnson & JohnsonXarelto$11$57,99056 claims
GSKAnoro Ellipta, Trelegy Ellipta, Shingrix$155$37,72550 claims
Lilly USA, LLCMounjaro$234$18,71220 claims
Esperion Therapeutics, Inc.Nexlizet$64$7,83613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Supply

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →